Array Biopharma, Inc. (ARRY) Misses Q3 EPS by 4c; to Commence MEK162 Phase 3
Tweet Send to a Friend
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q3 EPS of ($0.19), $0.04 worse than the analyst estimate of ($0.15). Revenue for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
